Vertex Pharmaceuticals (VRTX) announced a significant regulatory milestone with the US FDA’s approval of its gene therapy, Casgevy (exagamglogene autotemcel), for an expanded indication. The approval now covers children as young as two years old diagnosed with either sickle cell disease or β thalassemia, broadening the treatment’s potential patient population.
This latest regulatory decision marks the eighth approval granted under the Commissioner’s National Priority Voucher pilot, underscoring the therapy’s importance in addressing critical unmet medical needs. Casgevy, a gene-editing treatment, offers a novel approach for these severe genetic blood disorders.
The expansion to include very young children represents a crucial step for Vertex, potentially impacting future revenue streams and solidifying its position in the gene therapy market. For patients and their families, this approval provides an earlier therapeutic option for managing these debilitating conditions.
